Characterization of IDO1 and TDO2 in pediatric central nervous system tumors

被引：0
|
作者：
Lauing, Kristen
Lulla, Rishi
Zhai, Lijie
Hashizume, Rintaro
Fangusaro, Jason
Wainwright, Derek A.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2016年 / 4卷 / 11期
关键词：
D O I：
10.1158/2326-6066.IMM2016-A051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A051
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Reiterative Chiral Resolution/Racemization/Recycle (RRR Synthesis) for an Effective and Scalable Process for the Enantioselective Synthesis of a Dual IDO1/TDO2 Inhibitor Imidazoisoindole Derivative
    Crescenzi, Cristina
    Fuchss, Thomas
    Ippoliti, Dimitri
    Langella, Annunziata
    Di Mola, Antonia
    Massa, Antonio
    Rozzi, Diego
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2020, 24 (06) : 1018 - 1023
  • [32] Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
    Chunjing Wu
    Sydney A. Spector
    George Theodoropoulos
    Dan J. M. Nguyen
    Emily Y. Kim
    Ashley Garcia
    Niramol Savaraj
    Diane C. Lim
    Ankita Paul
    Lynn G. Feun
    Michael Bickerdike
    Medhi Wangpaichitr
    Cancer & Metabolism, 11
  • [33] A comprehensive analysis of TDO2 expression in immune cells and characterization of immune cell phenotype in TDO2 knockout mice
    Susu Li
    Siyu Li
    Yingjie Zhao
    Bingjie Zhang
    Xinwei Wang
    Xuezhi Yang
    Yueye Wang
    Chengyan Jia
    Yan Chang
    Wei Wei
    Transgenic Research, 2021, 30 : 781 - 797
  • [34] The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma
    Miyasato, Yuko
    Takashima, Yasuo
    Takeya, Hiroto
    Yano, Hiromu
    Hayano, Azusa
    Nakagawa, Takenobu
    Makino, Keishi
    Takeya, Motohiro
    Yamanaka, Ryuya
    Komohara, Yoshihiro
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2018, 58 (02) : 95 - 101
  • [35] Discovery of novel isothiourea derivatives as potent dual inhibitors of IDO1 and TDO
    Ogo, Naohisa
    Muraoka, Daisuke
    Ando, Takayuki
    Asai, Akira
    CANCER SCIENCE, 2021, 112 : 557 - 557
  • [36] Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO
    Feng, Xi
    Shen, Pei
    Wang, Yinuo
    Li, Zhiyu
    Bian, Jinlei
    BIOCHEMICAL PHARMACOLOGY, 2019, 168 : 214 - 223
  • [37] Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2
    Tijono, Sofian M.
    Palmer, Brian D.
    Tomek, Petr
    Flanagan, Jack U.
    Henare, Kimiora
    Gamage, Swarna
    Braun, Lukas
    Ching, Lai-Ming
    PHARMACEUTICALS, 2022, 15 (09)
  • [38] Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
    Meininger, David
    Zalameda, Leeanne
    Liu, Yichin
    Stepan, Lara P.
    Borges, Luis
    McCarter, John D.
    Sutherland, Claire L.
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2011, 1814 (12): : 1947 - 1954
  • [39] IDO1 and TDO inhibitory evaluation of analogues of the marine pyrroloiminoquinone alkaloids: Wakayin and Tsitsikammamines
    Levy, Thomas
    Marchand, Laura
    Stroobant, Vincent
    Pilotte, Luc
    Van den Eynde, Benoit
    Rodriguez, Frederic
    Delfourne, Evelyne
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 40
  • [40] Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
    Cheong, Jae Eun
    Sun, Lijun
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2018, 39 (03) : 307 - 325
12345